{"id":"411d348d-58b3-5d66-9722-c227ba0a1687","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-double-mutant-palmit-null","predicate":"has_contextual_experimental_result","statement":"Solasonine did not increase STAT3 palmitoylation in the reported APT2-D13A/L11A mutant setting.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"295b21f9-f631-573c-8dae-1c9f061f46fd","mechanism_event_label":"ss-apt2-double-mutant-palmit-null","subject":{"id":"93f78c96-4def-5373-8bcb-2c54e0b8152b","slug":"human-apt2-d13a-l11a-solasonine-gbc","display_name":"APT2-D13A/L11A expression with solasonine in human gallbladder cancer cells","entity_type_key":"protein_state"},"object":{"id":"2bb7e799-f77a-5a72-b8d6-3ec458cc11aa","slug":"human-stat3-palmitoylation","display_name":"STAT3 palmitoylation in human cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"295b21f9-f631-573c-8dae-1c9f061f46fd","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:ss-apt2-double-mutant-palmit-null","event_type":"experimental_result","label":"ss-apt2-double-mutant-palmit-null","description":"Solasonine did not increase STAT3 palmitoylation in the reported APT2-D13A/L11A mutant setting.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"93f78c96-4def-5373-8bcb-2c54e0b8152b","slug":"human-apt2-d13a-l11a-solasonine-gbc","display_name":"APT2-D13A/L11A expression with solasonine in human gallbladder cancer cells","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"2bb7e799-f77a-5a72-b8d6-3ec458cc11aa","slug":"human-stat3-palmitoylation","display_name":"STAT3 palmitoylation in human cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"f2ffef5b-5457-50a8-b787-b8f24430f610","slug":"lypla2","display_name":"LYPLA2","entity_type_key":"protein"},"role":"mutated protein","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"6410ac1a-e95f-550f-955a-6725a3765ee3","slug":"solasonine","display_name":"Solasonine","entity_type_key":"small_molecule"},"role":"exposure","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"dc129d3d-aaa0-5511-9a60-3e3880b0eb0f","slug":"stat3","display_name":"STAT3","entity_type_key":"protein"},"role":"measured protein","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"experimental_model","value_text":"Human NOZ and GBC-SD gallbladder cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Methods 2.2 describes 48-hour cellular drug treatments with refresh at 24 hours; exact concentration must be checked per figure and is not inferred from another assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"Figure 6E; Supplementary Figure S5A; Results 3.6.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1002/ptr.70245","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"b4767fe6-7d3e-5043-a6f5-0674c9dd77d2","evidence_kind":"source_excerpt","locator":"Lines 159-165","start_line":159,"end_line":165,"excerpt":"Solasonine did not increase STAT3 palmitoylation in the reported APT2-D13A/L11A mutant setting.\nprimary_references: https://doi.org/10.1002/ptr.70245\nprimary_locator: Figure 6E; Supplementary Figure S5A; Results 3.6.\norganism: Human\nexperimental_model: Human NOZ and GBC-SD gallbladder cancer cells\nexposure: Methods 2.2 describes 48-hour cellular drug treatments with refresh at 24 hours; exact concentration must be checked per figure and is not inferred from another assay.\nlimitations: Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","model_system":"Human NOZ and GBC-SD gallbladder cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curator paraphrase, not a publisher quotation. Methodological inference is explicitly identified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"15a55d0b-bd44-54e4-9080-5526d1a9744d","stable_key":"import-d71929ae-ed38-52ed-b512-f92b9b148b71","title":"APT2, STAT3 and GPX4: opposing branches and assay qualification","document_type":"imported_text","citation_label":"Primary observations: 10.1038/s41467-025-56344-5 and 10.1002/ptr.70245; selected full-text review 2026-09-20.","file_path":"","sha256":"6fd94803c436074e7b2c15e9a817e751c3d95f6fe1d35a4af63ab641a8f33fe0","revision_id":"d59d5472-18d2-5feb-bc2e-529ceda00956","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}